SAGIMET BIOSCIENCES INC.

SAGIMET BIOSCIENCES is a clinical-stage biopharmaceutical company that develops new therapeutic agents called fatty acid synthase inhibitors.

The company does not yet have any approved drugs for use in the US and EU. However, SAGIMET BIOSCIENCES' drugs are currently in clinical trials and have already shown promising results in a group of 600 people.
 

The company plans to offer 4.69 million shares at a price ranging from $15.00 to $17.00 to raise $75.0 million.

__________________________________________

Number of employees:

10

___________________________________________

Headquarters:

155 Bovet Road, Suite 303 San Mateo, California 94402